PTC Updatse on R&D Pipeline, Commercial Progress at JPM

  ~$333 million preliminary unaudited 2020 total net product revenue representing 14% year-over-year growth -

- Huntington splicing program healthy volunteer data expected 1H 2021 -

- Multiple late-stage clinical programs advancing with six registration-directed trials -

- 2021 Duchenne franchise revenue guidance of $355-$375 million -

2021 Financial Guidance:

• PTC anticipates full year net product revenues for the DMD franchise to be between $355 and $375 million.
• PTC anticipates GAAP R&D and SG&A expense for the full year 2021 to be between $825 and $855 million.
• PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2021 to be between $725 and $755 million, excluding estimated non-cash, stock-based compensation expense of approximately $100 million.

https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-update-on-rd-pipeline-and-commercial-progress-at-39th-annual-jp-morgan-healthcare-conference-301204949.html